NASDAQ:SGMO - Sangamo Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.10 +0.75 (+5.23 %)
(As of 07/17/2018 09:45 AM ET)
Previous Close$14.35
Today's Range$14.45 - $15.1252
52-Week Range$8.00 - $27.50
Volume105,503 shs
Average Volume2.34 million shs
Market Capitalization$1.53 billion
P/E Ratio-21.57
Dividend YieldN/A
Beta2.92
Sangamo Therapeutics logoSangamo Therapeutics, Inc. focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop the preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGMO
CUSIP80067710
Phone510-970-6000

Debt

Debt-to-Equity Ratio0.14
Current Ratio4.78
Quick Ratio4.78

Price-To-Earnings

Trailing P/E Ratio-21.57
Forward P/E Ratio-23.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.57 million
Price / Sales41.91
Cash FlowN/A
Price / CashN/A
Book Value$2.22 per share
Price / Book6.80

Profitability

EPS (Most Recent Fiscal Year)($0.70)
Net Income$-54,560,000.00
Net Margins-126.96%
Return on Equity-30.96%
Return on Assets-20.75%

Miscellaneous

Employees182
Outstanding Shares101,500,000
Market Cap$1,527.50

The Truth About Cryptocurrencies

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by $0.52. The biopharmaceutical company had revenue of $12.60 million for the quarter, compared to the consensus estimate of $53.09 million. Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. Sangamo Therapeutics's quarterly revenue was up 270.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.23) EPS. View Sangamo Therapeutics' Earnings History.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Sangamo Therapeutics.

What price target have analysts set for SGMO?

6 equities research analysts have issued 12 month price objectives for Sangamo Therapeutics' shares. Their predictions range from $8.00 to $30.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $22.50 in the next year. This suggests a possible upside of 49.0% from the stock's current price. View Analyst Ratings for Sangamo Therapeutics.

What is the consensus analysts' recommendation for Sangamo Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:
  • 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (7/17/2018)
  • 2. Wedbush analysts commented, "We traveled with VBI management last week in Boston and noted good reception and enthusiasm around the lead program Sci-B-Vac for Hepatitis B. Enrollment is proceeding well in Phase 3, which we anticipate could be complete during 2Q18. VBI still expects top-line Phase 3 data in mid-2019, which we expect to easily show non- inferiority to GSK’s Engerix-B, and which could show superiority in adults age 45 or older. Interestingly, VBI will also measure seroprotection after 2 doses of Sc-B-Vac vs 3 doses of Engerix-B, which we expect to be positive for Engerix-B as well. In our view, over the long-term, Sci-B-Vac could show a profile suggesting 2 dose protection in patients of all ages, greatly expanding the market opportunity, which we conservatively project to be $370M WW." (3/13/2018)

Who are some of Sangamo Therapeutics' key competitors?

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:
  • Dr. Alexander D. Macrae, CEO, Pres & Director (Age 55)
  • Ms. Kathy Y. Yi, Sr. VP & CFO (Age 46)
  • Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 45)
  • Dr. Michael Holmes, Sr. VP & CTO
  • Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations

Has Sangamo Therapeutics been receiving favorable news coverage?

News coverage about SGMO stock has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.60%), Handelsbanken Fonder AB (0.35%), Cito Capital Group LLC (0.05%), Franklin Street Advisors Inc. NC (0.04%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Which major investors are buying Sangamo Therapeutics stock?

SGMO stock was acquired by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Peregrine Capital Management LLC, Franklin Street Advisors Inc. NC, Cito Capital Group LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $15.10.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.53 billion and generates $36.57 million in revenue each year. The biopharmaceutical company earns $-54,560,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 182 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]


MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  502
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.